Investors who bought Chemours stock between February 20 and August 4, 2026 may be covered by a proposed securities class action alleging Chemours overstated aftermarket demand for its Opteon refrigerants and issued unreliable 2026 guidance. No class has been certified and there is nothing to file yet.
Allegations Only · No Settlement Yet
This article describes a class action complaint. The statements below are unproven allegations. The Chemours Company, Denise Dignam and Shane Hostetter have not been found liable, there is no certified class, and nothing to claim at this time. This page is informational and is not legal advice.
What Is This About?
A Chemours shareholder filed a proposed securities class action on October 8, 2026, in the U.S. District Court for the District of Delaware. The case is Darcy v. The Chemours Company, No. 1:26-cv-01299. Besides the Wilmington, Delaware chemical maker, which trades on the New York Stock Exchange as CC, the complaint names President and CEO Denise Dignam and CFO Shane Hostetter. It alleges that while Chemours promoted record sales of its Opteon refrigerants and repeatedly backed its 2026 earnings guidance, the company was overstating aftermarket demand that had been pulled forward into 2025. The defendants have not yet responded in court.Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
What Does the Lawsuit Allege?
Chemours reports its refrigerant sales in its Thermal & Specialized Solutions segment. Its Opteon products are lower-impact refrigerants, and the company told investors that growth in the segment was supported in part by the American Innovation and Manufacturing Act, the 2020 federal law directing a shift away from older refrigerants.According to the complaint, Chemours reported a record fourth quarter for Opteon in February 2026, with 37% growth, and guided to adjusted EBITDA of $800 million to $900 million for 2026. On the February 2026 earnings call, Dignam said the company had “full confidence in our full year guide,” and Hostetter said double-digit Opteon growth was expected to continue into the second quarter. The company reaffirmed the guidance with first-quarter results in May 2026, citing in part higher demand in the segment.
The plaintiff says those statements were misleading because they left out that:
- Chemours had materially overstated aftermarket demand for its Opteon products;
- demand was falling because the company had oversold Opteon in the prior year; and
- as a result, its 2026 financial guidance was unreliable.
The complaint also alleges that during the class period Dignam sold 23,439 Chemours shares for about $426,876 and Hostetter sold 3,232 shares for about $58,952. These are the plaintiff’s claims; no court has made findings on them.
The August 2026 Stock Drop
After the market closed on August 4, 2026, Chemours reported second-quarter results and cut its full-year adjusted EBITDA guidance to $775 million to $825 million, from $800 million to $900 million. According to the complaint, management said on the earnings call that “as a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026,” and that about $65 million of aftermarket sales “probably should have been allocated” to 2026. Chemours stock fell $3.34, or 18.63%, to close at $14.59 on August 5, 2026.The figures come from the complaint. Whether the decline was caused by the alleged misstatements, rather than by ordinary business news, is a question the court has not reached.
Who Is in the Proposed Class?
The complaint defines the class as all persons and entities, other than the defendants, that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, inclusive, and were damaged. It brings claims under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 against all defendants, and under Section 20(a), the “control person” provision, against Dignam and Hostetter. It seeks damages, interest, costs and fees, and a jury trial. The plaintiff is represented by Pomerantz LLP.This investor case is separate from Chemours’ environmental litigation, including the PFAS settlement with the Justice Department.
What Happens Next?
Under the Private Securities Litigation Reform Act, the notice published by the plaintiff’s counsel on October 8, 2026 sets December 7, 2026 as the deadline for investors to ask the court to be appointed lead plaintiff — the investor, usually one with a large loss, who directs the case for the class. That step is optional. Under the law, an investor who does not seek lead-plaintiff status can still be part of any class the court later certifies, subject to the final class definition and any later claims process.After the court appoints a lead plaintiff and lead counsel, an amended complaint is typically filed and the defendants usually move to dismiss. Securities class actions often take years, and many are dismissed; there is no guarantee of certification, settlement or recovery. There is no settlement and no claim form today. OCA will update this page as the case develops.
Questions
Who is covered by the Chemours securities class action?
The complaint proposes a class of all persons and entities, other than the defendants, that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, inclusive, and were damaged. No class has been certified.
What is the lead plaintiff deadline in the Chemours case?
The notice published by the plaintiff’s counsel under the Private Securities Litigation Reform Act lists December 7, 2026 as the deadline to ask the court to be appointed lead plaintiff. Seeking that role is optional. Under the law, investors who do not seek it can still be members of any class the court later certifies.
Is there a Chemours securities settlement or claim form?
No. The case was filed on October 8, 2026 and is at the complaint stage. There is no settlement, no certified class and no claim form. If the case ever settles, the court would approve a notice explaining any claim process and deadline.
What is Opteon and why does it matter to the lawsuit?
Opteon is Chemours’ line of lower-impact refrigerants sold for air conditioning and refrigeration, which the company said was benefiting from the federal AIM Act’s transition away from older refrigerants. The complaint alleges Chemours overstated aftermarket demand for Opteon after customers had built up inventory in 2025.
Is this related to the Chemours PFAS settlement?
No. This is an investor lawsuit over statements about Opteon refrigerant demand and 2026 earnings guidance. It is separate from Chemours’ PFAS environmental cases and settlements.
Sources
• Darcy v. The Chemours Company, No. 1:26-cv-01299 (D. Del.) — docket and complaint• Pomerantz LLP — PSLRA notice of the filing and lead plaintiff deadline, October 8, 2026
• Chemours — Form 10-Q for the quarter ended June 30, 2026
